Apel­lis jumps on the cash train af­ter FDA ap­proves its GA drug

Fol­low­ing Apel­lis Phar­ma­ceu­ti­cals’ sec­ond FDA ap­proval, the biotech plans to raise sub­stan­tial cash to kick-start com­mer­cial­iza­tion ef­forts.

The Mass­a­chu­setts biotech

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER